ERBB2 and breast cancer: Similarly, Hudelist et al (39) reported that pHER2Y1248-positive staining was the only covariate predicting the benefit of trastuzumab-based treatment in metastatic BC patients exhibiting moderate or strong HER2 overexpression (39).